Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nutriband Inc WT
(NQ:
NTRBW
)
1.230
-0.240 (-16.33%)
Streaming Delayed Price
Updated: 3:31 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,856
Open
1.550
Bid (Size)
0.7500 (15)
Ask (Size)
1.850 (1)
Prev. Close
1.470
Today's Range
1.170 - 1.550
52wk Range
0.1885 - 3.440
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
July 19, 2024
Via
ACCESSWIRE
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
July 15, 2024
Via
ACCESSWIRE
Performance
YTD
+310.14%
+310.14%
1 Month
-28.90%
-28.90%
3 Month
+29.47%
+29.47%
6 Month
+286.06%
+286.06%
1 Year
+35.16%
+35.16%
More News
Read More
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
June 20, 2024
Via
ACCESSWIRE
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
June 03, 2024
Via
ACCESSWIRE
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
May 16, 2024
Via
ACCESSWIRE
Nutriband Inc. Announces $8.4M Private Placement
April 19, 2024
Via
ACCESSWIRE
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
January 29, 2024
Via
ACCESSWIRE
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
September 20, 2023
Via
ACCESSWIRE
Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
September 12, 2023
Via
ACCESSWIRE
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
April 24, 2024
Via
ACCESSWIRE
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
April 23, 2024
Via
ACCESSWIRE
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
April 01, 2024
Via
ACCESSWIRE
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
March 27, 2024
Via
ACCESSWIRE
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
March 25, 2024
Via
ACCESSWIRE
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
March 04, 2024
Via
ACCESSWIRE
Nutriband CEO Publishes Letter to Shareholders
January 26, 2024
Via
ACCESSWIRE
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
January 05, 2024
Via
ACCESSWIRE
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
November 28, 2023
Via
ACCESSWIRE
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
November 08, 2023
Via
ACCESSWIRE
Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
October 11, 2023
Via
ACCESSWIRE
Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications
September 20, 2023
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
September 20, 2023
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
September 20, 2023
Via
News Direct
Topics
Intellectual Property
Exposures
Intellectual Property
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
September 20, 2023
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
September 20, 2023
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.